Arie Belldegrun raises $300M, grabs Pfizer’s allogeneic CAR-T portfolio and launches a groundbreaking drive to commercialization

After pioneering one of the first personalized CAR-T therapies to be approved by the FDA, Kite vets Arie Belldegrun and research chief David Chang have now launched a new biotech with a whopping $300 million in cash financing and a collaboration with Cellectis after bagging the full portfolio of off-the-shelf CAR-T drugs in development at … Continue reading Arie Belldegrun raises $300M, grabs Pfizer’s allogeneic CAR-T portfolio and launches a groundbreaking drive to commercialization